

We Claim:

1 1. (original) A pharmaceutical composition comprising a tailored α_1 -
2 adrenoceptor antagonist, a bladder-selective antagonist and optionally included 5 α -reductase
3 inhibitor, optionally together with pharmaceutically acceptable carriers, excipients or diluents.
1 2. (original) The pharmaceutical composition according to claim 1 wherein the
2 tailored α_1 AR antagonist is selective for α_{1a} over α_{1b} subtype but non-selective for α_{1a} over
3 α_{1d} subtype.

1 3. (original) The pharmaceutical composition according to claim 1 wherein the
2 tailored α_1 AR antagonist is more than about 10 fold selective for α_{1a} over α_{1b} subtype and is
3 less than about 10 fold selective for α_{1a} over α_{1d} subtype in receptor binding and *in vitro*
4 functional assay.

1 4. (currently amended) The pharmaceutical composition according to claim 3
2 wherein the tailored α_1 adrenoceptor antagonist is selected from:

3 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,
4 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-
5 1,3(2H)-dione,
6 5-[2-[(2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,
7 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,
8 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-
9 1,3(2H)-dione hydrochloride salt and
10 5-[2-[(2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide
11 hydrochloride salt,
12 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer,
13 racemate, polymorphs, N- oxides or metabolites.

14 5. (cancelled)

1 6.5. (currently amended) The pharmaceutical composition according to claim 1,
2 wherein the bladder selective antagonist is an agent which exhibits greater potency in
3 inhibiting the carbachol-induced response on the bladder than the carbachol-evoked salivation
4 when evaluated simultaneously in *in vivo* model in rabbit or dog.

5 7.6. (currently amended) The pharmaceutical composition according to claim 65
6 wherein the bladder- selective antagonist is selected from:
1 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
2 cyclopentyl-2-phenyl acetamide,
3 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl
4 acetate,
5 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-
6 phenyl acetate,
7 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]-hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-
8 phenyl acetate,
9 (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-
10 phenyl acetamide,
11 (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-
12 phenyl acetamide,
13 (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl
14 acetamide,
15 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
16 phenyl acetamide,
17 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]-hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl
18 acetamide,
19 N-[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-cyclopentyl-2-hydroxy-2-
20 phenyl acetamide,
21 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-
22 difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,
23 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
24 cyclohexyl-2-phenyl acetamide,
25 (1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-
26 cyclopentyl-2-phenyl acetamide,
27 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
28 diphenyl acetamide,
29 3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,
30 N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-
31 cyclopentyl-2-hydroxy-2-phenyl acetamide,
32 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphe-nyl)ethyl)-2-
33 cyclopentyl-2-hydroxy-2-phenyl acetamide,

34 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
35 hydroxy-2-phenyl acetamide, and

36 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
37 hydroxy-2-phenyl acetamide, and

38 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
39 cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,

40 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl
41 acetate L(+)-tartrate salt,

42 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-
43 phenyl acetate L(+)-tartrate salt,

44 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-
45 phenyl acetate L(+)-tartrate salt,

46 (2R)-(+)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
47 hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

48 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
49 cyclopentyl-2-phenyl acetamide hydrochloride salt,

50 (2R)- (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
51 cyclopentyl-2-phenyl acetamide hydrochloride salt,

52 (2S)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
53 cyclopentyl-2-phenyl acetamide hydrochloride salt,

54 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-
55 difluorocyclopentyl)-2-phenyl acetamide tartrate salt,

56 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
57 diphenyl acetamide

58 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
59 phenyl acetamide tartrate salt,

60 (2R, 2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-
61 phenyl acetamide hydrochloride salt,

62 N-{[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]}-2-cyclopentyl-2-hydroxy-2-
63 phenyl acetamide hydrochloride salt,

64 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-
65 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

66 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-
67 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

68 (2R, 2S)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
69 hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

70 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-
 71 2-cyclohexyl-2-phenyl acetamide tartrate salt,
 72 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-
 73 hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,
 74 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 75 cyclopentyl-2-phenyl acetamide tartrate salt,
 76 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
 77 diphenyl acetamide tartrate salt,
 78 2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl
 79 acetate hydrochloride,
 80 N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-
 81 cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,
 82 (2R) (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxophenyl)ethyl)-2-
 83 cyclopentyl-2-hydroxy-2-phenyl acetamide,
 84 (2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 85 hydroxy-2-phenyl acetamide succinate salt,
 86 (2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 87 hydroxy-2-phenyl acetamide L(+)-tartrate salt,
 88 (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline
 89 carboxylate,
 90 (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline
 91 carboxylate succinate salt,
 92 2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-
 93 (hydroxymethyl)phenyl ester and
 94 2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-
 95 (hydroxymethyl)phenyl ester with (2E)-2-butenedioate and
 96 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,
 97 diastereomers, polymorphs, N-oxide or metabolites.

98 8. (cancelled).

1 9-7. (currently amended) The pharmaceutical composition according to claim 1
 2 wherein said 5 α -reductase inhibitor is a type 1 or a type 2 or both a type 1 and type 2 or a dual
 3 type 1 and type 2 inhibitor.

1 10-8. (currently amended) The pharmaceutical composition according to claim 9-7
 2 wherein the 5 α -reductase inhibitor is a dual type 1 and type 2 inhibitor.

1 11. 9. (currently amended) The pharmaceutical composition according to claim ~~10~~ 8
2 wherein the dual type 1 and type 2 inhibitor is dutasteride.

1 12. 10. (currently amended) The pharmaceutical composition according to claim ~~9~~ 7
2 wherein the 5 α -reductase inhibitor is a type 2 inhibitor.

1 13. 11. (currently amended) The pharmaceutical composition according to claim ~~12~~ 10
2 wherein the type 2 inhibitor is finasteride.

1 14. 12 (currently amended) A pharmaceutical product or medicament comprising a
2 first pharmaceutical composition of a tailored α_1 adrenoceptor antagonist, a second
3 pharmaceutical composition of a bladder selective antagonist and optionally included a third
4 pharmaceutical composition of 5 α -reductase inhibitor.

1 15.13. (currently amended) A pharmaceutical product or medicament of claim ~~14~~ 12
2 wherein the product or medicament is a combined preparation.

1 16.14. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~15~~ 13 wherein the combined preparation is single dosage form.

1 17.15. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~15~~ 13 wherein the combined preparation comprises separate dosage forms.

1 18.16. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~14~~ 12 wherein the tailored α_1 AR antagonist is selective for α_{1a} over α_{1b} subtype but
3 non-selective for α_{1a} over α_{1d} subtype.

1 19.17. (currently amended) A pharmaceutical product or medicament according to
2 claim ~~14~~ 12 wherein the tailored α_1 AR antagonist is more than about 10 fold selective for α_{1a}
3 as compared to α_{1b} subtype and is less than about 10 fold selective for α_{1a} over α_{1d} subtype in
4 receptor binding and *in vitro* functional assay.

1 20.18. (currently amended) The pharmaceutical product or medicament according to
2 claim ~~19~~ 17 wherein the tailored α_1 adrenoceptor antagonist is selected from:
3 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,

4 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-
5 1,3(2H)-dione,
6 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,
7 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,
8 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-
9 1,3(2H)-dione hydrochloride salt and
10 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide
11 hydrochloride salt,
12 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer,
13 racemate, polymorphs, N- oxides or metabolites.

14 21. (cancelled).

15 22.19. (currently amended) A pharmaceutical product or medicament according to
16 claim 14-12 wherein the bladder-selective antagonist is an agent which exhibits greater
17 potency in inhibiting the carbachol-induced response on the bladder than the carbachol-
18 evoked salivation when evaluated simultaneously in *in vivo* model in rabbit or dog.

1 23.20. (currently amended) A pharmaceutical product or medicament according to
2 claim 22 19 wherein the bladder-selective antagonist is selected from:

3 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
4 cyclopentyl-2-phenyl acetamide,
5 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl
6 acetate,
7 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-
8 phenyl acetate,
9 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-
10 phenyl acetate,
11 (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-
12 phenyl acetamide,
13 (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-
14 phenyl acetamide,
15 (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl
16 acetamide,

17 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
 18 phenyl acetamide,
 19 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]-hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl
 20 acetamide,
 21 N-{[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6ylmethyl]}-2-cyclopentyl-2-hydroxy-2-
 22 phenyl acetamide,
 23 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-
 24 difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,
 25 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 26 cyclohexyl-2-phenyl acetamide,
 27 (1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-
 28 cyclopentyl-2-phenyl acetamide,
 29 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
 30 diphenyl acetamide,
 31 3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,
 32 N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-
 33 cyclopentyl-2-hydroxy-2-phenyl acetamide,
 34 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxophenyl)ethyl)-2-
 35 cyclopentyl-2-hydroxy-2-phenyl acetamide,
 36 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 37 hydroxy-2-phenyl acetamide, and
 38 (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
 39 hydroxy-2-phenyl acetamide, and
 40 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 41 cyclopentyl-2-phenyl acetamide L-(+)-tartrate salt,
 42 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl
 43 acetate L(+)-tartrate salt,
 44 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-
 45 phenyl acetate L(+)-tartrate salt,
 46 (1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]-hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-
 47 phenyl acetate L(+)-tartrate salt,
 48 (2R)-(+)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
 49 hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,
 50 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 51 cyclopentyl-2-phenyl acetamide hydrochloride salt,
 52 (2R)- (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
 53 cyclopentyl-2-phenyl acetamide hydrochloride salt,

54 (2S)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
55 cyclopentyl-2-phenyl acetamide hydrochloride salt,

56 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-
57 difluorocyclopentyl)-2-phenyl acetamide tartrate salt,

58 (2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
59 diphenyl acetamide

60 N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl)
61 phenyl acetamide tartrate salt,

62 (2R, 2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]-hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-
63 phenyl acetamide hydrochloride salt,

64 N-{[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]}-2-cyclopentyl-2-hydroxy-2-
65 phenyl acetamide hydrochloride salt,

66 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-
67 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

68 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-
69 3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

70 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-
71 hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

72 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-
73 2-cyclohexyl-2-phenyl acetamide tartrate salt,

74 (2R, 2S)-(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-
75 hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

76 (2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-
77 cyclopentyl-2-phenyl acetamide tartrate salt,

78 (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-
79 diphenyl acetamide tartrate salt,

80 2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl
81 acetate hydrochloride,

82 N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-
83 cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)-tartrate salt,

84 (2R) (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxophenyl)ethyl)-2-
85 cyclopentyl-2-hydroxy-2-phenyl acetamide,

86 (2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
87 hydroxy-2-phenyl acetamide succinate salt,

88 (2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-
89 hydroxy-2-phenyl acetamide L(+)-tartrate salt,

90 (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline
91 carboxylate,

92 (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline
93 carboxylate succinate salt,
94 2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-
95 (hydroxymethyl)phenyl ester and
96 2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-
97 (hydroxymethyl)phenyl ester with (2E)-2-butenedioate,
1 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers,
2 diastereomers, polymorphs, N-oxide or metabolites.

3 24. (cancelled).

1 25.21. (currently amended) A pharmaceutical product or medicament according to
2 claim 14 12 wherein the 5 α -reductase inhibitor is a type 1 or a type 2 or both a type 1 and
3 type 2 or a dual type 1 and type 2 inhibitor.

1 26. (cancelled).

1 27.22. (currently amended) A pharmaceutical product or medicament according to
2 claim 26 wherein the dual type 1 and type 2 inhibitor is dutasteride.

1 28. (cancelled).

1 29.23. (currently amended) A product or medicament according to claim 28 21
2 wherein the type 2 inhibitor is finasteride.

1 30.24. (currently amended) method for treatment of a mammal suffering from lower
2 urinary tract symptoms (LUTS) associated with or without BPH, comprising administering to
3 said mammal, a therapeutically effective amount of a product or medicament, comprising a
4 tailored α_1 AR antagonist, a bladder-selective antagonist and optionally included 5 α -reductase
5 inhibitor.

1 31. (cancelled).

1 32. (cancelled).

1 33.25. (currently amended) The method according to claim 32 24 wherein the
2 mammal is a human male.

1 34.26. (currently amended) The method according to claim 32 24 wherein the
2 mammal is a human female.

1 35. (cancelled).

2 36. (cancelled)

3 37. (cancelled).

4 39. (cancelled).

5 40. (cancelled).

1 41. 27. (currently amended) The method according to claim 30 24 wherein the
2 tailored α_1 AR antagonist is selective for α_{1a} over α_{1b} subtype but non-selective for α_{1a} over
3 α_{1d} subtype AR antagonist.

1 42.28. (currently amended) The method according to claim 30 24 wherein the tailored
2 α_1 AR antagonist is more than about 10 fold selective for α_{1a} as compared to α_{1b} subtype and
3 is less than about 10 fold selective for α_{1a} as compared to α_{1d} subtype in receptor binding and
4 functional assay.

1 43.29. (currently amended) The method according to claim 42 28 wherein the tailored
2 α_1 AR antagonist is selected from:

3 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione,
4 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-
5 1,3(2H)-dione,
6 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide,
7 1-{3-[4-(2-methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione hydrochloride salt,
8 2-[3-{4-(2-isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-
9 1,3(2H)-dione hydrochloride salt and

10 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide
11 hydrochloride salt,

1 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomer,
2 racemate, polymorphs, N- oxides or metabolites.

1 44. (cancelled).

2 45.30. (currently amended) The method according to claim 30 24 wherein the bladder-
3 selective antagonist is an agent which exhibits greater potency in inhibiting the carbachol-
4 induced response on the bladder than the carbachol-evoked salivation when evaluated
5 simultaneously in *in vivo* model in rabbit or dog.

46.31. (currently amended) The method according to claim 45 30 wherein the bladder-selective antagonist is selected from:

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide,

N-{[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]}-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate,

N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphenyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide, and

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2,2-diphenyl acetate L(+)-tartrate salt,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetate L(+)-tartrate salt,

(1 α , 5 α , 6 α)-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(methyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetate L(+)-tartrate salt,

(2R)-(+)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide L(+)-tartrate salt,

(2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R)- (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2S)-(1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide hydrochloride salt,

(2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-difluorocyclopentyl)-2-phenyl acetamide tartrate salt,

(2R, 2S) (1 α , 5 α , 6 α)-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide,

N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-phenyl-2-hydroxy-2-(N-methyl) phenyl acetamide tartrate salt,

(2R, 2S)-N-[(1 α , 5 α , 6 α)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-2-isopropyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

N-{[(1 α , 5 α , 6 α)-3-chloro-3-azabicyclo[3.1.0]hex-6-ylmethyl]}-2-cyclopentyl-2-hydroxy-2-phenyl acetamide hydrochloride salt,

(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1R or 1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-[(1S or 1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenyl acetamide tartrate salt,

(2R, 2S)- (1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide succinate salt,

(2R, 2S)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclohexyl-2-phenyl acetamide tartrate salt,

(2R, 2S)-(1 α , 5 α , 6 α)-N-[3-(1-phenylethyl)-3-azabicyclo[3.1.0]hexyl-6-(amino)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(2R)-(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-cyclopentyl-2-phenyl acetamide tartrate salt,

(1 α , 5 α , 6 α)-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide tartrate salt,

2R(+),4[(1R, 5S)-3-azabicyclo[3.1.0]hex-3-yl]but-2-ynyl-2-cyclopentyl-2-hydroxyphenyl acetate hydrochloride,

N-methyl-N-(1 α , 5 α , 6 α)-N-[3-(4-methyl-3-pentenyl)-3-azabicyclo[3.1.0]-hex-6-yl]-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)tartrate salt,

(2R) (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(3,4-methylenedioxyphe nyl)ethyl)-2-cyclopentyl-2-hydroxy-2-phenyl acetamide,

(2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide succinate salt,

(2R)- (1 α , 5 α , 6 α)-6-N-(3-azabicyclo[3.1.0]hexyl-3-(4-methyl-3-pentenyl))-2-cyclopentyl-2-hydroxy-2-phenyl acetamide L(+)tartrate salt,

(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate,

(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate succinate salt,

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester and

2-methyl propanoic acid 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester with (2E)-2-butenedioate.

their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs, N-oxides or metabolites.

47. (cancelled).

48. (cancelled).

49. (cancelled).

50. (cancelled).

51. (cancelled).

52. (cancelled).